Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson, P G; Hofmeister, C C; Raje, N S; Siegel, D S; Lonial, S; Laubach, J; Efebera, Y A; Vesole, D H; Nooka, A K; Rosenblatt, J; Doss, D; Zaki, M H; Bensmaine, A; Herring, J; Li, Y; Watkins, L; Chen, M S; Anderson, K C

Richardson, P G; Hofmeister, C C; Raje, N S; Siegel, D S; Lonial, S; Laubach, J; Efebera, Y A; Vesole, D H; Nooka, A K; Rosenblatt, J; Doss, D; Zaki, M H; Bensmaine, A; Herring, J; Li, Y; Watkins, L; Chen, M S; Anderson, K C.

Afiliação

Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. paul_richardson@dfci.harvard.edu.
Hofmeister CC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Raje NS; Massachusetts General Hospital, Boston, MA, USA.
Siegel DS; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Lonial S; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Laubach J; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Efebera YA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Vesole DH; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Nooka AK; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Rosenblatt J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Doss D; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Zaki MH; Celgene Corporation, Summit, NJ, USA.
Bensmaine A; Celgene Corporation, Summit, NJ, USA.
Herring J; Celgene Corporation, Summit, NJ, USA.
Li Y; Celgene Corporation, Summit, NJ, USA.
Watkins L; Celgene Corporation, Summit, NJ, USA.
Chen MS; Celgene Corporation, Summit, NJ, USA.
Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Leukemia ; 32(10): 2305, 2018 10.

Article em En | MEDLINE | ID: mdl-30218008

RESUMO

Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC cohort should be the maximum tolerated dose of 4 mg/day, not 2 mg/day as listed in the original Fig. 1. The authors apologize for any inconvenience caused.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google